2. Signaling Pathways
  3. Anti-infection
  4. Parasite
  5. Parasite Control

Parasite Control

Parasite Isoform Comparison

Parasite Controls (7):

Cat. No. Product Name Effect Purity
  • HY-N9991
    5-Hydroxy-3,7-dimethoxyflavone
    		Control 99.89%
    5-Hydroxy-3,7-dimethoxyflavone (compound 1) can be isolated from Kaempferia parviflora, but has no significant toxicity to malaria parasites, fungi, and bacteria.
  • HY-W112166
    (E/Z)-4,4'-Dicyanostilbene
    		Control 98.34%
    (E/Z)-4,4'-Dicyanostilbene is the isomer of 4,4'-Dicyanostilbene (HY-W112166A), and can be used as an experimental control. 4,4'-Dicyanostilbene (compound 43) is a potent antimalarial agent against the Dd2 strain, with an EC50 of 27 nM. 4,4'-Dicyanostilbene exhibits in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA).
  • HY-169445
    (±)-Meclonazepam
    		Control
    (±)-Meclonazepam ((±)-Ro 11-3128) is the racemate of Meclonazepam (HY-101725). Meclonazepam (Ro 11-3128) is a benzodiazepine compound with anxiolytic effect. Meclonazepam exhibits antischistosomal activity against S. mansoni.
  • HY-B1370E
    (R)-Hydroxychloroquine phosphate
    		Control
    (R)-Hydroxychloroquine ((R)-HCQ) phosphate is a (R)-isomer of Hydroxychloroquine (HY-W031727). (R)-Hydroxychloroquine inhibits the insulin metabolizing enzyme of cytosolic fraction of liver homogenates in healthy and diabetic rats.
  • HY-66035
    4-(Trifluoromethyl)nicotinic acid
    		Control
    4-(Trifluoromethyl)nicotinic acid (4-(Trifluoromethyl)pyridine-3-carboxylic acid) is a metabolite of the pyridinecarboxamide insecticide Flonicamid (HY-119649).
  • HY-W399186
    Methylclonazepam
    		Control
    Methylclonazepam is a benzodiazepine with anxiolytic activity. Methylclonazepam inhibits the absorption of 5-hydroxytryptamine by Schistosoma mansoni. Methylclonazepam derivatives have anti-Schistosoma mansoni activity.
  • HY-145530
    (S)-Hydroxychloroquine sulfate
    		Control
    (S)-Hydroxychloroquine ((S)-HCQ) sulfate is an isomer of Hydroxychloroquine (HY-W031727). (S)-Hydroxychloroquine sulfate (2.5-20 mg/mL) reduces the rate of insulin degradation in liver homogenates isolated from non-diabetic and diabetic rats. Formulations containing Hydroxychloroquine have been used in the study of malaria, rheumatoid arthritis, and systemic lupus erythematosus.